Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study

Clinical Infectious Diseases

Volumn 43, Issue 1, 2006, Pages 25-31

  Garey, Kevin W ^a   Rege, Milind ^a   Pai, Manjunath P ^b   Mingo, Dana E ^c   Suda, Katie J ^c   Turpin, Robin S ^d   Bearden, David T ^e  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CANCER; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CATHETERIZATION; CLINICAL TRIAL; DIABETES MELLITUS; EVALUATION RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; COHORT STUDIES; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33745313876     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504810     Document Type: Article

References (20)

1. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39:3254-9.
2. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26:540-7.
3. Miller LG, Hajjeh RA, Edwards JE Jr. Estimating the cost of nosocomial candidemia in the United States [letter]. Clin Infect Dis 2001; 32:1110.
4. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-8.
5. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
6. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
7. Ben-Abraham R, Keller N, Teodorovitch N, et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004; 49:317-23.
8. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004; 39:1161-9.
9. Harbarth S, Ferriere K, Hugonnet S, Ricou B, Suter P, Pittet D. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002; 137:1353-9 [discussion, 1359].
10. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
11. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004; 23:380-8.
12. Pappas PG, Rex JH. Therapeutic approach to Candida sepsis. Curr Infect Dis Rep 1999; 1:245-52.
13. Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol 2002; 23:542-5.
14. Safdar A, Cross EW, Chaturvedi V, Perlin DS, Armstrong D. Prolonged candidemia in patients with cancer. Clin Infect Dis 2002; 35:778-9.
15. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998; 31:327-32.
16. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
17. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16:533-7.
18. von Baum H, Ober JF, Wendt C, Wenzel RP, Edmond MB. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population? Infection 2005; 33:320-6.
19. Leinberger DM, Schumacher U, Autenrieth IB, Bachmann TT. Development of a DNA microarray for detection and identification of fungal pathogens involved in invasive mycoses. J Clin Microbiol 2005; 43:4943-53.
20. Bu R, Sathiapalan RK, Ibrahim MM, et al. Monochrome LightCycler PCR assay for detection and quantification of five common species of Candida and Aspergillus. J Med Microbiol 2005; 54:243-8.